Company News2025-04-15

TJ Biopharma Announces Completion of Patient Enrollment in Phase 2 Clinical Study of Uliledlimab for NSCLC

Company News2025-04-07

TJ Biopharma Joins Biogen-Sponsored Phase 3 Multi-Regional Clinical Trials of Felzartamab in IgAN and PMN

Company News2025-01-10

TJ Biopharma Announces NMPA Acceptance of BLA for Felzartamab in Multiple Myeloma

Company News2024-12-09

TJ Biopharma and Jumpcan Jointly Announce China NMPA Acceptance of BLA for Eftansomatropin Alfa

Company News2024-09-20

TJ Biopharma’s Plonmarlimab Granted Breakthrough Therapy Designation in China

Company News2024-05-23

Felzartamab Demonstrates Positive Results in Two Phase 2 Studies Presented at ERA 2024

Media Coverage2024-03-27

TJ Biopharma Initiates Phase II/III NSCLC Study: Uliledlimab-Toriparlimab Combo vs. Keytruda

Company News2024-02-07

TJ Biopharma Secures $700 Million in C1 Funding, Announces Strategic Restructuring

• 1